ICS therapy shows most CV benefit in COPD patients with eosinophilia 

COPD patients with higher levels of eosinophils are more at risk of experiencing a cardiac event if not receiving an inhaled corticosteroid (ICS) as part of their therapy, according to a post hoc analysis of data from the ETHOS trial. Presenting the findings at ERS 2021, Professor Mona Bafadhel, Respiratory Physician and COPD research group ...

Already a member?

Login to keep reading.

© 2021 the limbic